In the previous project FFC#13/2019, the research group confirmed the correlation between mutated CFTR and the lack of activation of the integrin LFA-1 (Lymphocyte function-associated antigen-1). This observation suggests that the quantification of LFA-1 activation in monocytes can be a specific marker of CFTR activity. In this project, an extension of the previous one, the goal is to demonstrate that the measurement of LFA-1 activation in monocytes can be used to monitor the outcome of treatments of persons with cystic fibrosis (CF) with the drugs Katrio (Trikafta) and Symkevi. The study will be carried out on peripheral blood samples from healthy donors and from persons with CF with type II or III mutations, before and during therapy. The proposed approach could improve the predictive and monitoring capacity for new CFTR corrective therapies, thus allowing a personalized approach to the treatment of CF.

XIX Convention FFC Ricerca – download here a brief presentation of the project